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Summary An 86-year-old woman was admitted to the hospital for syncope and convulsion
4 days after starting antibiotic therapy for pneumonia with oral garenoxacin 400mg/day.
She had a VDD pacemaker for complete atrioventricular (AV) block. Her electrocardiogramQT interval;
Torsades de pointes
showed marked QT prolongation and during pacemaker interrogation pacing failure probably
due to battery depletion induced torsades de pointes. After cessation of garenoxacin, QTc
returned to normal range subsequently and a new pacemaker was implanted. In patients
with risks of QT prolongation, garenoxacin should be used cautiously with QT interval
monitoring.
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arenoxacin is a novel quinolone that possesses antimi-
robial activity against a wide range of bacteria. Like all
uoroquinolones, garenoxacin has the potential to induce
orsades de pointes (TdP) but is thought to have the less QT
rolonging effects [1]. This is the ﬁrst case of torsades de
ointes induced by garenoxacin in a patient without con-
omitant electrolyte imbalance and other QT prolonging
edication.
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ase report
n 86-year-old woman was admitted to the hospital
or pneumonia and antibiotic therapy with garenoxacin
00mg/day had been started for 4 days. The patient had
yncope and convulsion one day after initiating oral admin-
stration of garenoxacin. She was referred to our hospital
or closer examination of syncope and convulsion. VDD type
acemaker was implanted for complete atrioventricular
AV) block 10 years before. On admission, electrocardio-
raphy showed ventricular pacing at 65/min (VVI mode)
robably due to pacemaker battery depletion. The QTc
nterval according to Bazett’s formula was prolonged to
.68 s (Fig. 1). To shorten the prolonged QT interval, repro-
ramming of the pacing rate up to 80/min was attempted,
Published by Elsevier Ltd. All rights reserved.
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eFigure 1 Electrocardiogram (ECG) on admission. On admission
shows inverted T wave in V2 and V3 with prolonged QT interval
but pacing failure occurred suddenly during interrogation.
Prolonged RR interval increased QT interval further and
induced TdP (Fig. 2).
Her echocardiography showed diffuse hypokinesis of the
left ventricle and decreased left ventricular ejection frac-
tion of 25%. Laboratory data showed K of 3.9mEq/L, Ca of
8.9mg/dL, and Mg of 1.9mg/dL. Serum level of creatine
kinase was increased slightly at 226 IU/L, but creatine kinase
MB fraction was not elevated (9 IU/L). Serum cardiac tro-
ponin I was negative. Serum concentration of garenoxacin
on admission was 3.0g/mL and it remained within the
therapeutic range. No other QT prolonging drug was admin-
istered on admission. On the following day, garenoxacin was
discontinued and a new VDD pacemaker was implanted.
Pacing rate was changed from 40/min to 80/min gradu-
ally and QT/RR relation was evaluated (Fig. 3). The slope
of linear regression line of QT/RR relation was increased
to 0.25. QTc returned to normal level (0.46 s) 14 days
after cessation of garenoxacin with a basic pacing rate of
60/min.
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Figure 2 Induction of torsades de pointes during pacemaker interromode changed to VVI mode because of battery depletion. ECG
erisk indicates P wave.
iscussion
nhibition of HERG channel currents by quinolones leads to
rolongation of QT interval [2]. Milberg et al. demonstrated
hat several ﬂuoroquinolones (ciproﬂoxacin, oﬂoxacin, mox-
ﬂoxacin, and levoﬂoxacin) increased QT interval and
nduced TdP associated with greater disparity of repolar-
zation and triangulation of action potential in AV blocked
abbit hearts [3]. Sparﬂoxacin and grepaﬂoxacin had been
ithdrawn from the market because of proarrhythmia due
o TdP.
In our case, QT/RR relation was examined using
mplanted pacemaker the day after TdP episodes. The slope
f QT/RR regression line (0.25) was steeper and was sim-
lar to the long QT syndrome type 2 patients because of
xcessive prolongation of QT interval at long RR intervals
4]. Steeper slope of QT/RR regression line is compatible
ith suppression of IKr induced by quinolones. TdP was trig-
ered by the escape beat with a prolonged RR interval due to
entricular pacing failure. Not only the prolonged RR inter-
gation. A long-short RR sequence preceded torsades de pointes.
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[igure 3 Electrocardiogram during changes in pacing rate.
0/min. QT interval was increased in association with RR interv
al but also the different depolarization sequence prolonged
oth QT interval and T peak to end intervals further (Fig. 2).
Garenoxacin had no clinically relevant dose-dependent
ffects on the QT interval across a dose range from
0 to 1200mg/day in the retrospective analysis of data
rom healthy volunteers [1]. Although QT-prolonging effects
f garenoxacin seem to be lower than the other ﬂu-
roquinolones, there has been reported one case with
arenoxacin-induced TdP [5]. An 82-year-old man had TdP
fter oral administration of garenoxacin for pneumonia. He
ad hypokalemia and also had disopyramide and the combi-
ation of electrolyte imbalance and class Ia antiarrhythmic
rug in itself may induce prolonged QT interval and TdP. On
he other hand, our case had no hypokalemia and had not
ad the other QT prolonging drug. As the pathogenesis of
iffuse hypokinesis of the left ventricle, dilated cardiomy-
pathy seems to be the most probable because she had
o history of coronary artery disease and no sign of sec-
ndary cardiomyopathy such as sarcoidosis. Hence, a direct
ffect of garenoxacin on QT prolongation and TdP induction
as suspected. The prolonged RR interval induced by pace-
aker malfunction due to battery depletion may also play
n important role for the trigger of TdP episodes. It is rec-
mmended that like all other ﬂuoroxacins [6], garenoxacin
hould be used cautiously in patients with risks of QT prolon-
ation such as female sex, advanced age, and bradycardia.
[ricular pacing rate was decreased gradually from 80/min to
olongation.
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